TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

114 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Kidney disease

    Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis

    Testing amino acid supplements during hemodialysis for fatigue and thinking in end-stage kidney

    📍 The University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →

    The study will test and compare the efficacy of a single essential amino acid valine with a combination of essential amino acids (EAA) supplement on fatigue, frailty, and cognitive function in end-stage kidney disease (ESKD) patients undergoing hemodialysis (HD) treatment.

    ✓ Study care freeEarly Phase 1Ages 18–64Learn more →
  • Kidney disease

    📍 Mayo Clinic in Arizona · Scottsdale, AZ · +4 more US sites · Get directions →

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

    Testing whether a tributyrin supplement helps memory, thinking, and balance in adults with Parkinson

    📍 Domino's Farms · Ann Arbor, MI · Get directions →

    The goal of this clinical trial is to learn if taking a tributyrin supplement works to improve memory and thinking and walking and balance in adults with Parkinson disease Parkinson disease dementia. It will also learn about the safety of tributyrin supplementation.

    ✓ Study care freePhase 1Ages 45+Learn more →
  • Sickle cell disease

    A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

    Testing different doses of DISC-3405 to check safety in sickle cell disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +6 more US sites · Get directions →

    This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Dementia / Alzheimer's

    A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

    Testing the safety and how a drug works in people with Alzheimer’s

    📍 Clinical Trial Site · Montreal, · Get directions →

    The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration

    ✓ Study care freePhase 1Ages 40–80Learn more →
  • Sickle cell disease

    Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease

    Testing higher doses of VAS-101 in people with stable sickle cell disease

    💵 May compensate

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Sickle cell disease (SCD) is an inherited blood disorder. The disease affects the ability of red blood cells to carry oxygen.

    ✓ Study care freePhase 1Ages 18–90Learn more →
  • Kidney disease

    Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

    Testing whether empagliflozin changes kidney filter injury proteins in African American Veterans

    📍 Washington DC Veterans Affairs Medical Center (688) · Washington D.C., DC · Get directions →

    Primary Objective:To study podocyte specific injury markers in African American Veterans with non-diabetic kidney disease(NDKD), on empagliflozin therapy. Primary Endpoint: Assess the effect of Empagliflozin on podocyte-specific proteins in exosomes isolated from subjects' urine, such as nephrin, podocalyxin and Wilms'Tumor (WT-1) protein.

    ✓ Study care freePhase 4Ages 19–90Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    PET Imaging Evaluation of [11C]SY08

    Testing a PET scan tracer to detect alpha-synuclein protein clumps in dementia and Parkinson’s

    📍 MGH · Charlestown, MA · Get directions →

    The overall goal of the proposed research is to evaluate the use of \[11C\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to evaluate the use of \[11C\]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls.

    ✓ Study care freeEarly Phase 1Ages 50–80Learn more →
  • Dementia / Alzheimer's

    Rifaximin SSD in Dementia Trial

    Testing a new form of rifaximin to change gut microbes in people with dementia

    📍 Richmond VA Medical Center · Richmond, VA · Get directions →

    Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.

    ✓ Study care freePhase 1Ages 65+Learn more →
  • Kidney disease

    📍 SouthCoast Research Center, Inc. · Miami, FL · +1 more US site · Get directions →

    The goal of this clinical trial is to learn about the safety (good or bad) of giving two AION-301 intravenous (IV) infusions, in adults with Stage 3 Chronic Kidney Disease (CKD). It will also help to learn if AION-301 reduces the symptoms of CKD and/or progression.

    ✓ Study care freePhase 1Ages 35–75Learn more →
  • Sickle cell disease

    A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

    Testing the safety and how an oral carbon monoxide liquid works in sickle cell disease

    📍 Cevaxin - The Panama Clinic · Panama City, · Get directions →

    This is a multi-center, open label Phase 2a clinical trial in subjects with sickle cell disease to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally administered liquid containing carbon monoxide (CO), with doses daily for 14 days.

    ✓ Study care freePhase 1Ages 18–55Learn more →
  • Dementia / Alzheimer's

    A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

    Testing a gene therapy in people with a genetic form of frontotemporal dementia

    📍 The Ohio State University (OSU) Wexner Medical Center · Columbus, OH · +2 more US sites · Get directions →

    The goal of this clinical study is to learn about an investigational gene therapy product called AVB-101, which is designed to treat a disease called Frontotemporal Dementia with Progranulin Mutations (FTD-GRN). FTD-GRN is an early-onset form of dementia, a progressive brain disorder that affects behavior, language and movement.

    ✓ Study care freePhase 1Ages 30–75Learn more →
  • Dementia / Alzheimer's

    SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy

    Using brain scans to study how HIV affects the brain during treatment

    📍 Yale School of Medicne, Neuro ID Research Program · New Haven, CT · Get directions →

    The purpose of this study is to longitudinally characterize and evaluate changes in synaptic density in the brain using novel positron-emission tomography (PET) scans; magnetic resonance imaging (MRI), and clinical laboratory markers associated with HIV-related injury in the central nervous system. This study will test hypotheses relating to the presence and mechanisms of aberrant brain structure at the synaptic level in living humans with virologically controlled HIV on antiretroviral therapy.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Dementia / Alzheimer's

    Exploration of an Online Education Program to Support Caregivers' Knowledge Transfer

    Testing an online program to help dementia caregivers share what they learn

    📍 Texas Christian University · Fort Worth, TX · +1 more US site · Get directions →

    The overarching goal of this work is to determine methods that improve caregiver education about the behavioral and psychological symptoms (BPSD) of dementia. The specific goal of this project is to extend our prior work to evaluate the impact of our educational intervention on caregivers' ability to transfer knowledge about the management of ADRD to real-world applied examples.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Kidney disease

    Intradialytic Exercise Combined With Creatine Monohydrate in Patients With Chronic Kidney Disease Undergoing Hemodialysis.

    Testing whether exercise during dialysis and creatine help people with chronic kidney disease

    📍 IMSS-Bienestar State Haemodialysis Centre · Colima, Coliima · Get directions →

    This study aims to evaluate the effects of creatine monohydrate supplementation and an intradialytic exercise program on body composition, biochemical parameters, and functional capacity in patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis. The study will compare the independent and combined effects of these interventions over an 8-week period to determine their potential benefits in this patient population.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Kidney disease

    Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease

    Testing kidney disease drug effects and safety in teens with early CKD

    💵 May compensate

    📍 Instituto de atención Integral de Enfermedades Renales del Estado de Aguascalientes · Aguascalientes, Aguascalientes · Get directions →

    Chronic kidney disease (CKD) is highly prevalent in the state of Aguascalientes, Mexico, particularly among adolescents and young adults. Epidemiologic and histologic studies suggest that this burden is largely driven by reduced nephron endowment of prenatal origin, leading to compensatory glomerular hyperfiltration, adaptive podocytopathy, and persistent albuminuria at early stages of disease.

    ✓ Study care freePhase 4Ages 14–18Learn more →
  • Sickle cell disease

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

    Testing whether extra arginine lowers pain in children with sickle cell

    📍 Children's Healthcare fo Atlanta at Hughes Spalding · Atlanta, GA · +1 more US site · Get directions →

    The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.

    ✓ Study care freePhase 1Ages 7–21Learn more →
  • Kidney disease

    Randomised Evaluation of Sodium Dialysate Levels on Vascular Events

    Testing whether two dialysate salt levels affect heart events and death

    📍 Royal Adelaide Hospital · Adelaide, · Get directions →

    This global study will assess the effect of randomising dialysis sites to one of two default dialysate sodium concentrations in current practice, 140mmol/l and 137mmol/l, on major cardiovascular events and death in patients receiving maintenance haemodialysis.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Dementia / Alzheimer's

    Ferritin and Iron Burden in SAH sIRB

    Testing how iron and ferritin levels relate to brain injury after ruptured aneurysms with dementia

    📍 Univesity of Iowa Hospital and Clinics · Iowa City, IA · +1 more US site · Get directions →

    Ruptured cerebral aneurysms lead to subarachnoid hemorrhage (SAH),that has a high morbidity and mortality rate, the severity of which is predicted by the "Hunt-Hess grade" (HHG). SAH leads to iron (Fe) and hemoglobin (Hb) accumulation in the brain, which is toxic for neurons.

    ✓ Study care freePhase 1Ages 18–75Learn more →
  • Dementia / Alzheimer's

    Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease

    Studying whether ovarian hormones are linked to aging and Alzheimer’s risk in women

    📍 Mayo Clinic · Jacksonville, FL · +1 more US site · Get directions →

    The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.

    ✓ Study care freePhase 4Ages 60+WomenLearn more →
  • Type 2 diabetesKidney disease

    Mechanism of SGLT2 Inhibition in the Kidney

    Testing how SGLT2 medicines affect kidney function in type 2 diabetes

    💵 May compensate

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in Type 2 diabetes. We are looking for participants 18-80 years of age, who have had a clinical diagnosis of Type 2 diabetes for ≥ 3 years.

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Kidney disease

    A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function

    Testing how a diabetes medicine in the bloodstream changes in kidney disease

    📍 Floridian Clinical Research, LLC · Miami Lakes, FL · +1 more US site · Get directions →

    The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants. The study drug will be administered subcutaneously (SC) (under the skin).

    ✓ Study care freePhase 1Ages 18–85Learn more →
  • Sickle cell disease

    RH Genotype Matched RBC Transfusions

    Testing whether matching donor red blood cells by RH type helps people with sickle cell who need

    📍 Children's Hospital of Philadelphia · Philadelphia, PA · Get directions →

    To determine the feasibility and efficacy of matching donor red cells by RH genotype for a cohort of chronically transfused patients with SCD.

    ✓ Study care freePhase 1Ages 1+Learn more →
  • Dementia / Alzheimer's

    A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

    Testing a medicine in people with dementia to lower brain tau protein

    📍 Washington University in St. Louis · St Louis, MO · Get directions →

    This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells.

    ✓ Study care freePhase 1Ages 21–80Learn more →
  • Dementia / Alzheimer's

    Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

    Testing a treatment called SNK01 in people with moderate Alzheimer’s disease

    📍 Behavioral Research Specialists, LLC · Glendale, CA · +6 more US sites · Get directions →

    The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: 1.

    ✓ Study care freePhase 1Ages 40–85Learn more →
  • Kidney disease

    Concomitant Renal and Urinary Bladder Allograft Transplantation

    Testing whether transplanting a new kidney and bladder at the same time is possible for people with

    📍 Mayo Clinic · Rochester, MN · +1 more US site · Get directions →

    The purpose of this study is to establish if concomitant renal and vascularized urinary bladder allograft transplantation is feasible.

    ✓ Study care freeEarly Phase 1Ages 1–60Learn more →
  • Sickle cell disease

    Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease

    Testing a one-time blood stem cell transplant using gene editing for severe sickle cell disease

    📍 University of California, Los Angeles · Los Angeles, CA · +1 more US site · Get directions →

    This is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SCD). The study will evaluate the hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9 edited red blood cells (known as CRISPR\_SCD001 Drug Product).

    ✓ Study care freePhase 1Ages 12–35Learn more →
  • Kidney disease

    Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR)

    Testing a daily anti-inflammatory medicine to reduce heart and blood vessel injury in people with

    📍 University of Alberta Hospital · Edmonton, Alberta · Get directions →

    Phase 1 basket trial including 2 open-label single-arm cohorts: REPAIR CKD cohort and REPAIR Dialysis cohort. Open label colchicine 0.3 mg daily for 8 weeks followed, in patients who tolerated the 0.3 mg dose, by forced titration to 0.6 mg daily for 8 weeks.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Kidney disease

    Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease

    Testing whether a trial of SGLT2 inhibitors in youth with chronic kidney disease is feasible

    📍 Ann & Robert H. Lurie Children's Hospital of Chicago · Chicago, IL · Get directions →

    The goal of this study is to learn if a clinical trial of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is possible in youth with chronic kidney disease (CKD). The investigators also plan to explore whether treatment with SGLT2i (Empagliflozin) helps improve risk factors for worsening kidney and heart disease.

    ✓ Study care freeEarly Phase 1Ages 12–25Learn more →
  • Kidney disease

    Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD

    Testing a GE xenokidney transplant in people with ESRD for safety and effectiveness

    📍 Northwestern Memorial Hospital · Chicago, IL · +1 more US site · Get directions →

    The purpose of this study is to evaluate the safety and efficacy of the 10 GE Xenokidney in patients with ESRD who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2). The study consists of xenotransplantation followed by a 24-week Post-transplant Follow up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, 10 GE Xenokidney survival, and screening for zoonotic infections.

    ✓ Study care freePhase 1Ages 40–70Learn more →
  • Dementia / Alzheimer'sMultiple sclerosis (MS)

    Exploring the Utility of [18F]3F4AP for Demyelination Imaging

    Testing how an imaging tracer works in people with memory loss and multiple sclerosis

    📍 Yale University PET Center · New Haven, CT · Get directions →

    The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).

    ✓ Study care freePhase 1Ages 18–90Learn more →
  • DepressionDementia / Alzheimer's

    Aβ Dynamics in LLMD

    Testing how treating depression may change brain markers linked to Alzheimer’s

    📍 NYU Langone Health · New York, NY · +1 more US site · Get directions →

    This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and associated risk is to treat the depressive symptoms and examine the effects on AD biomarkers.

    ✓ Study care freePhase 4Ages 60+Learn more →
  • Sickle cell disease

    Cannabidiol in Sickle Cell Disease

    Testing twice-daily cannabidiol doses for people with sickle cell disease

    📍 Icahn School of Medicine at Mount Sinai · Manhattan, NY · Get directions →

    Randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Dementia / Alzheimer's

    Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease

    Testing how a new medicine works in healthy adults and early Alzheimer’s disease

    📍 Research Site 3 · East York, Ontario · Get directions →

    Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Type 2 diabetesKidney disease

    Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease

    Testing whether people with type 2 diabetes have early hormone-related kidney risk

    📍 Brigham and Women's Hospital · Boston, MA · Get directions →

    The aim of this protocol is to assess the presence and severity of primary aldosteronism pathophysiology in patients with type 2 diabetes who have, or are at-risk for developing, chronic kidney disease.

    ✓ Study care freeEarly Phase 1Ages 18–80Learn more →
  • Sickle cell disease

    Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease

    Testing whether routine red blood cell transfusions in pregnancy reduce sickle cell flare-ups or

    📍 Grady Health System · Atlanta, GA · Get directions →

    The goal of this study is to determine if there is a positive effect of prophylactic red blood cell (RBC) transfusion of leukoreduced, ABO, Rh (D/Cc/Ee) and Kell matched blood compared to standard of care on the number of episodes of acute sickle cell disease (SCD) manifestations or pregnancy-related complications requiring acute health care encounters (acute care/ER/Hospital visits) or resulting in death over the entirety of pregnancy until 2 months post-partum in women with SCD. RBC transfusion is the only disease-modifying therapy for pregnant women with SCD, and it is considered a standard treatment option however, there exists no consensus on the role of transfusion therapy in preventing SCD-related pregnancy complications.

    ✓ Study care freePhase 4Ages 18+WomenLearn more →
  • Sickle cell disease

    Gene Editing For Sickle Cell Disease

    Testing whether gene editing is safe for people with sickle cell disease

    📍 St. Jude Children's Research Hospital · Memphis, TN · Get directions →

    This study is being done to test the safety of a new treatment called gene editing in Sickle Cell Disease (SCD) patients and to see if a single dose of this genetically modified cellular product will increase the amount of a certain hemoglobin called fetal hemoglobin (HbF) and help reduce the symptoms of SCD. Primary Objective * To assess the safety of autologous infusion of clustered regularly interspaced palindromic repeats (CRISPR)/ CRISPR associated protein (Cas9)-edited CD34+ hematopoietic stem and progenitor cells (HSPCs) in patients with severe SCD.

    ✓ Study care freePhase 1Ages 18–24Learn more →
  • Kidney disease

    Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

    Testing the safety and side effects of OJR520 and how the body handles it in people with chronic

    📍 Quotient Sciences Sea View · Miami, FL · Get directions →

    The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Dementia / Alzheimer's

    TREAD: Time Restricted Eating Intervention for Alzheimer's Disease

    Testing time-limited eating to see if it improves sleep and brain changes in early Alzheimer’s or

    📍 Shiley Marcos Alzheimer's Disease Center · San Diego, CA · Get directions →

    The goal of this clinical trial is to learn if restricting the time of eating to allow for prolonged fasting at night may reduce sleep disturbances, cognitive decay, and pathology in patients diagnosed with Mild Cognitive Impairment (MCI) or early to moderate Alzheimer's disease (AD). It will also learn about the feasibility of practicing 14 h of nightly fasting in this group of older adults.

    ✓ Study care freePhase 1Ages 60+Learn more →
  • Dementia / Alzheimer's

    A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

    Testing the safety and effects of ACI-24.060 in Alzheimer’s and Down syndrome

    📍 Barrow Neurological Institute · Phoenix, AZ · +12 more US sites · Get directions →

    The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.

    ✓ Study care freePhase 1Ages 35–85Learn more →
  • Kidney disease

    Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD

    Testing a new kidney tissue transplant to treat end-stage kidney disease

    📍 New York University Langone Health · New York, NY · Get directions →

    The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2). The study consists of xenotransplantation followed by a 24-week Post-transplant Follow-up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, GGTA1 KO Thymokidney survival, and screening for zoonotic infections.

    ✓ Study care freePhase 1Ages 40–70Learn more →
  • Kidney disease

    📍 Research Site · Glendale, CA · +4 more US sites · Get directions →

    This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV) infusion. Additionally, the study investigates the non-interventional feasibility of home measurement of serum creatinine in participants with diabetic kidney disease (DKD).

    ✓ Study care freePhase 1Ages 18–75Learn more →
  • Kidney disease

    BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

    Testing a vaccine to prevent Epstein-Barr virus cancer in transplant patients

    📍 Ohio State University Comprehensive Cancer Center · Columbus, OH · Get directions →

    This phase 1B trial tests the safety, side effects and best dose of rh-Hsc70- BZLF1 peptide complex (OSU-2131) with Stimulon (Trademark) QS-21 and evaluates how well it works in preventing Epstein-Barr virus (EBV) infection and related cancers in healthy volunteers and patients awaiting a solid organ transplant. Currently, patients who receive an organ transplant receive immune suppression therapy which can make it harder for the body to fight infections.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Kidney disease

    A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease

    Testing the safety and how an oral medicine moves through the body in adults with severe kidney

    📍 Floridian Clinical Research · Miami Lakes, FL · +1 more US site · Get directions →

    This study will be conducted to assess the safety and pharmacokinetics of INCB123667 when administered orally to adult participants with severe renal impairment or end stage renal disease.

    ✓ Study care freePhase 1Ages 18–85Learn more →
  • Dementia / Alzheimer's

    Nicotinic Acid for the Treatment of Alzheimer's Disease

    Testing how well extended-release niacin reaches spinal fluid in dementia

    📍 IU Health Neuroscience Center · Indianapolis, IN · Get directions →

    Increased dietary intake of niacin is correlated with reduced risk of Alzheimer's Disease and age-associated cognitive decline. The goal of this study is to collect data on the penetration of commercially available, FDA approved, extended-release niacin into the spinal fluid.

    ✓ Study care freePhase 1Ages 60–85Learn more →
  • Dementia / Alzheimer's

    A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

    Testing whether a new drug is safe in people with early Alzheimer’s

    📍 K2 Medical Research, LLC · Maitland, FL · +5 more US sites · Get directions →

    The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD.

    ✓ Study care freePhase 1Ages 50–85Learn more →
  • Dementia / Alzheimer's

    Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)

    Testing deep rTMS on a brain area for people with probable Alzheimer dementia to see if it is safe

    📍 UCLA TMS Clinical and Research Service · Los Angeles, CA · Get directions →

    The goal of this clinical trial is to learn if using deep repetitive transcranial magnetic stimulation (rTMS) targeting the precuneus is feasible, tolerable, and potentially efficacious for memory in Probable Alzheimer's Dementia. Previous work studying rTMS in Alzheimer's is mixed, but recent work studying rTMS of the precuneus is encouraging for both its short-term and long-term effects.

    ✓ Study care freePhase 1Ages 60–100Learn more →
  • Sickle cell disease

    A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

    Testing how BMS-986470 affects the body and safety in sickle cell disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +18 more US sites · Get directions →

    The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Kidney disease

    Breakthrough - T1DM and Chronic Kidney Disease

    Testing an experimental treatment of Tegoprubart plus islet cells for diabetes and chronic kidney

    📍 The University of Chicago · Chicago, IL · Get directions →

    Single arm- subject treated with Tegoprubart and everolimus. The purpose of this research is to gather information on the safety and effectiveness of investigational regimen containing 2 experimental components: * An investigational drug called Tegoprubart and * Human pancreatic islet cells Both Tegoprubart and human pancreatic islet cells are considered investigational because they are not approved for use in the United States by the Food and Drug Administration (FDA).

    ✓ Study care freePhase 1Ages 18–70Learn more →
  • Sickle cell disease

    Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling

    Measuring how long red blood cells last in sickle cell disease

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Sickle cell disease (SCD) is an inherited disorder of the blood. SCD causes red blood cells (RBCs) to die early.

    ✓ Study care freeEarly Phase 1Ages 18–100Learn more →
  • Sickle cell disease

    Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

    Testing a partial stem cell transplant from matched donors for severe sickle cell disease or

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions. The intensity of the transplant is slightly increased from our previous transplant regimens.

    ✓ Study care freePhase 1Ages 4–65Learn more →
  • Sickle cell disease

    Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

    Testing how safe escalating doses of fostamatinib are in people with stable sickle cell disease

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Sickle cell disease (SCD) is a genetic disease that causes the body to produce abnormal ( sickled ) red blood cells. SCD can cause anemia and life-threatening complications in the lungs, heart, kidney, and nerves.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Sickle cell disease

    Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies

    Testing gene editing in stem cells for severe sickle cell disease

    📍 Boston Children's Hospital · Boston, MA · Get directions →

    A promising approach for the treatment of genetic diseases is called gene therapy. Gene therapy is a relatively new field of medicine that uses genetic material (mostly DNA) from the patient to treat his or her own disease.

    ✓ Study care freePhase 1Ages 13–40Learn more →
  • Dementia / Alzheimer's

    A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

    Testing the safety and effects of ABBV-1758 in people with Alzheimer’s disease given as injections

    📍 Irvine Center for Clinical Research /ID# 277752 · Irvine, CA · +10 more US sites · Get directions →

    Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness.

    ✓ Study care freePhase 1Ages 50–90Learn more →
  • Dementia / Alzheimer's

    Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD)

    Testing a rideshare with a trained driver to help people with dementia get to medical visits

    📍 Onward Health HQ · San Leandro, CA · Get directions →

    The goal of this pilot randomized controlled trial is to assess the impact of D2D rideshare services with a trained companion driver on the rate of medical appointments for older adults and individuals with AD/ADRD. Participants will be assigned either door-through-door (D2D) rideshare or curb-to-curb (C2C) rideshare services.

    ✓ Study care freePhase 1Ages 60+Learn more →
  • Dementia / Alzheimer's

    Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia

    Testing an education and support group for people with progressive aphasia and their caregivers

    📍 University of Texas at Austin · Austin, TX · Get directions →

    The current study aims to examine the benefits of an education/support group program for individuals with progressive aphasia (caused by various etiologies, diagnoses) and their carepartners. The current study utilizes pre-, post-treatment, and follow-up assessments to measure effects of a psychoeducational support group and an implementation/communication skills training phase on measures of psychosocial function, communicative effectiveness and speech/language function.

    ✓ Study care freeEarly Phase 1Ages 18+Learn more →
  • Dementia / Alzheimer's

    Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease

    Testing whether rTMS affects memory and brain function in dementia

    📍 Massachusetts General Hospital · Boston, MA · Get directions →

    In this research study we want to learn more about the effects of non-invasive brain stimulation on memory and brain-network function in cognitively unimpaired older adults and in patients with amnestic mild cognitive impairment (aMCI). This study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS).

    ✓ Study care freeEarly Phase 1Ages 40–99Learn more →
  • Dementia / Alzheimer's

    A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

    Testing the safety and side effects of Zunveyl in people with mild to moderate Alzheimer’s

    📍 Tekton Research Saint Louis Psychiatry · St Louis, MO · Get directions →

    The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.

    ✓ Study care freePhase 4Ages 50+Learn more →
  • Dementia / Alzheimer's

    AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)

    Testing a vaccine for early Alzheimer’s disease biomarkers for safety

    📍 Comprehensive Center for Brain Health · Boca Raton, FL · +2 more US sites · Get directions →

    This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple dose-escalating trial to evaluate the safety, tolerability, and immune response of AV-1980R, an investigational vaccine targeting tau protein, in participants with preclinical Alzheimer's disease. Up to 48 cognitively unimpaired adults aged 65-80 with biomarker evidence of early Alzheimer's disease will be enrolled into three ascending dose cohorts.

    ✓ Study care freePhase 1Ages 65–80Learn more →
  • Dementia / Alzheimer's

    📍 Montreal Neurological Institute Clinical Research Unit · Montreal, Quebec · Get directions →

    This study aims to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics following administration of RO7812653 in participants with eAD.

    ✓ Study care freePhase 1Ages 50–75Learn more →
  • Showing the first 60 of 114. Add filters or a location to narrow down.